Startup profile · funding coverage
ArkeaBio funding, valuation and investors
Climate-biotech company developing vaccines intended to reduce methane emissions from livestock.
Keep track of ArkeaBio
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A2
$15 million · September 30, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$45M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Charlestown, Massachusetts, United States
Overview
Boston-area ArkeaBio is developing a vaccine that prompts livestock immune systems to target methane-producing microbes in the rumen. The company is prioritizing New Zealand as its first commercial market.
Why ArkeaBio is interesting
A vaccine could fit existing animal-health workflows better than daily feed additives, but adoption depends on repeatable emissions reduction, regulatory approval and farmer economics. The Series A2 finances a focused commercialization path after a workforce reduction.
Product & use cases
ArkeaBio’s lead program is a livestock vaccine intended to induce antibodies against methane-producing rumen microbes. The company is targeting regulatory approval in New Zealand and initial sales in 2028.
- Reducing enteric methane emissions from cattle.
- Potential integration with existing livestock vaccination workflows.
Key facts
- Raised a $15 million Series A2 led by AgriZeroNZ in September 2026.
- Targets New Zealand regulatory approval before a planned 2028 commercial launch.
- Reduced headcount by about one-third while concentrating resources on the first product and market.
Funding history (newest first)
Series A2
2026-09-30 $15 millionSource: https://agfundernews.com/exclusive-arkeabio-raises-15m-for-livestock-methane-tech-cuts-headcount
Series A1
2025-09 $3.5 million follow-on investmentSource: https://www.farmersweekly.co.nz/news/agrizeronz-steps-up-support-for-methane-vaccine/
Series A
2024-05-08 $26.5 million- Breakthrough Energy Ventures (lead)
- The Grantham Foundation (participant)
- AgriZeroNZ (participant)
- Rabo Ventures (participant)
- Overview Capital (participant)
- The51 Food & AgTech Fund (participant)
Investors in our directory
Funds linked from ArkeaBio's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: A periodic vaccine could use familiar livestock-handling channels and avoid the daily administration required by many feed-additive approaches.
Competes with methane-reduction feed additives, seaweed-based supplements, selective breeding and microbiome interventions. Vaccine durability, efficacy, regulatory validation and cost per tonne of avoided emissions are the critical comparisons.
-
CH4 Global alternative
Develops seaweed-based livestock feed products intended to reduce methane.
-
Mootral alternative
Develops feed additives for enteric-methane reduction.
-
Rumin8 alternative
Develops feed supplements targeting livestock methane.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover ArkeaBio's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.